All In Biotech

NDA 022275 · Otsuka

Samsca

Tolvaptan · Oral · Vasopressin V2 Receptor Antagonist

Novel

Last checked: Nov 20, 2026Latest source record: Apr 22, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

May 19, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

104

40 Phase 3, 3 recruiting

FAERS reports

14,926

11,890 serious, 3,255 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: (A) INITIATE AND RE-INITIATE IN A HOSPITAL AND MONITOR SERUM SODIUM (B) NOT FOR USE FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) WARNING: (A) INITIATE AND RE-INITIATE IN A HOSPITAL AND MONITOR SERUM SODIUM (B) NOT FOR USE FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) See full prescribing information for complete boxed warning. (A) Initiate and re-initiate in a hospital and monitor serum sodium SAMSCA should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction...

What it is approved for

From the label in effect May 7, 2026.

SAMSCA ® is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). SAMSCA is a selective vasopressin V 2 -receptor antagonist indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia [serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction], including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH) ( 1 ) Limitations of Use: Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with SAMSCA ( 1 ) It has not been established that SAMSCA provides a symptomatic benefit to patients ( 1 ) Limitations of Use Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with SAMSCA. It has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients.

Mechanism: Tolvaptan is a selective vasopressin V 2 -receptor antagonist with an affinity for the V 2 -receptor that is 1.8 times that of native arginine vasopressin (AVP). Tolvaptan affinity for the V 2 -receptor is 29 times greater than for the V 1a -receptor. When taken orally, 15 to 60 mg doses of tolvaptan antagonize the effect of vasopressin and cause an increase in urine water excretion that results in an increase in free water clearance (aquaresis), a decrease in urine osmolality, and a resulting increase in serum sodium concentrations. Urinary excretion of sodium and potassium and plasma...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • SAMSCA · TOLVAPTAN 30MG · TABLET, ORAL · Prescription · TE AB1
  • SAMSCA · TOLVAPTAN 60MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • SAMSCA · TOLVAPTAN 15MG · TABLET, ORAL · Prescription · TE AB1

Clinical trials

Interventional ClinicalTrials.gov studies with "Tolvaptan" as an intervention, any sponsor and status, largest first.

All 104 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death1,042
  • thirst1,011
  • off label use888
  • renal impairment884
  • cardiac failure828
  • product dose omission issue779
  • pollakiuria602
  • wrong technique in product usage process535
  • product use in unapproved indication501
  • underdose498
  • dehydration481
  • no adverse event481

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
200914
201043
2011128
2012345
2013430
2014357
2015531
2016744
2017889
20181,079
20191,238
2020761
20211,018
20221,022
20231,068
20241,521
20252,027
20261,710

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Samsca (Tolvaptan)

2024 spending

$8.7M

Beneficiaries

110

639 claims

Per beneficiary

$79,468

$498.05 per unit

View as table
YearSpending
2020$62,691,940
2021$38,557,079
2022$30,575,697
2023$12,363,435
2024$8,741,488

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 228 on PubMed

Sponsor: Otsuka

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.